As another 3-HMG-CoA-reductase inhibitor, rosuvastatin was tested versus placebo for its efficacy in ARDS in the SAILS study (Statins for Acutely Injured Lungs from Sepsis). This evidence concerns the gene HMGCR and Sepsis.